ClearPoint Neuro Inc vs Under Armour Inc Class A — how do they compare? ClearPoint Neuro Inc trades at $14.57 (market cap $454.21M), while Under Armour Inc Class A trades at $5.22 (market cap $2.26B). The key difference: Under Armour Inc Class A is far larger — about 5× ClearPoint Neuro Inc's market cap. Which is the better fit depends on your goals.
| CLPT | UAA | |
|---|---|---|
Market Cap | $454.21M | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $8.14 |
52-Week Low | $8.66 | $4.17 |
Enterprise Value | $488.79M | $3.24B |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Under Armour (UAA) trades at $5.86, down 4.09% today, reflecting ongoing challenges. The stock shows a bearish technical trend with support near $5.00. Fundamentally, the company reported a net loss of -$201.27M in 2025 with a negative net margin of -9.99%, though recent Q2 2026 earnings beat expectations. Revenue declined to $5.16B in 2025, and cash flow turned negative at -$361.87M. Analyst sentiment is mixed with a consensus price target of $6.67 but a majority hold rating.
The outlook remains cautious due to weak North American demand and margin pressures. Investment opportunities exist if the company executes its full-price strategy successfully, but risks include persistent revenue declines and high debt levels. The stock's proximity to its low price target of $5.00 underscores downside vulnerability.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →